Medical Oncology, Journal Year: 2024, Volume and Issue: 42(1)
Published: Dec. 24, 2024
Language: Английский
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 375 - 375
Published: March 15, 2025
Recent progress in material science has led to the development of new drug delivery systems that go beyond conventional approaches and offer greater accuracy convenience application therapeutic agents. This review discusses evolutionary role nanocarriers, hydrogels, bioresponsive polymers enhanced release, target accuracy, bioavailability. Oncology, chronic disease management, vaccine are some applications explored this paper show how these materials improve results, counteract multidrug resistance, allow for sustained localized treatments. The also translational barriers bringing advanced into clinical setting, which include issues biocompatibility, scalability, regulatory approval. Methods overcome challenges surface modifications reduce immunogenicity, scalable production methods such as microfluidics, harmonization systems. In addition, convergence artificial intelligence (AI) machine learning (ML) is opening frontiers personalized medicine. These technologies predictive modeling real-time adjustments optimize needs individual patients. use can be applied rare underserved diseases; thus, strategies gene therapy, orphan drugs development, global distribution may hopes millions
Language: Английский
Citations
2
Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106900 - 106900
Published: April 1, 2025
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113824 - 113824
Published: May 1, 2025
Language: Английский
Citations
0
ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown
Published: May 12, 2025
RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering (siRNA). However, the clinical application of siRNA-based treatments faces challenges such rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery revolutionized therapy by addressing these limitations, improving stability, tumor-specific targeting, therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance safety precision therapies, offering new opportunities personalized medicine. This review highlights three key innovations nanotechnology-enhanced delivery: artificial intelligence (AI)-driven design, multifunctional nanoparticles combined strategies, biomimetic nanocarriers enhanced biocompatibility. AI-driven utilize machine learning algorithms optimize nanoparticle properties, drug release profiles minimizing off-target effects. Multifunctional integrate with chemotherapy, immunotherapy, or photothermal synergistic treatment approaches that outcomes reduce resistance. Biomimetic nanocarriers, including exosome-mimicking systems cell-membrane-coated nanoparticles, improve circulation time, evasion, targeted tumor delivery. These collectively precision, efficiency, therapies. The scope novelty lie their ability overcome primary barriers while paving way clinically viable solutions. provides comprehensive analysis latest developments fabrication, preclinical studies, assessments. By integrating multifunctionality, biomimicry, holds immense potential future therapy.
Language: Английский
Citations
0
Published: Jan. 1, 2025
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: Aug. 29, 2024
Background Pancreatic cancer (PC), sometimes referred to as pancreatic ductal adenocarcinoma (PDAC), is a major cause of global mortality from cancer. very aggressive and devastating kind cancer, characterized by limited options for therapy low possibilities survival. Sulforaphane (SFN), naturally occurring sulfur-containing compound, believed possess anti-inflammatory, anti-obesity, anti-cancer characteristics. Objective However, efficient preventative treatment measures are essential SFN has been studied its ability suppress cell proliferation induce apoptosis. Methods Here, induced cytotoxicity apoptosis in PDAC lines such MIA PaCa-2 PANC-1 cells, evaluated cytotoxicity, colony formation, western blot analysis, fluorescence-activated sorting (FACS), reactive oxygen species (ROS) detection, caspase-3 activity assay, immunofluorescence mitochondrial membrane potential assay. Results In inhibited survival dose-dependent manner. The activation caspase zymogens results cleaved PARP caspase-3, which associated with an accumulation the sub G1 phase. Furthermore, increased ROS level γH2A.X expression while decreasing (ΔΨm). Notably, scavenger N-Acetyl-L-cysteine (NAC) was shown reverse SFN-induced level. Subsequently, cycle arrest induction Trojan horse eliminate cells via ROS-mediated pathways were used inhibit cells. Conclusion Collectively, our data demonstrates that death follows pathway, making it viable target therapeutic interventions against
Language: Английский
Citations
3
Nano-Structures & Nano-Objects, Journal Year: 2024, Volume and Issue: 39, P. 101321 - 101321
Published: Sept. 1, 2024
Language: Английский
Citations
3
Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(10), P. 5238 - 5246
Published: Sept. 24, 2024
Heat shock protein 90 (Hsp90) is a promising target for cancer therapy and imaging. Accurate detection of Hsp90 levels in tumors via noninvasive PET imaging might be beneficial management. To achieve this, the precursor compound Dimer-Sansalvamide A (Dimer-San A) was PEGylated modified by conjugating it with bifunctional chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). The
Language: Английский
Citations
2
Biology Methods and Protocols, Journal Year: 2024, Volume and Issue: 9(1)
Published: Jan. 1, 2024
Abstract Pancreatic cancer is an aggressive malignancy with a poor prognosis. Single-nucleotide mutations in the KRAS gene are detected majority of patients pancreatic ductal adenocarcinoma (PDAC), most common type cancer. Identifying by liquid biopsy could be effective for detecting de novo and recurrent PDAC; however, sensitive accurate detection remains challenging. We examined utility oligoribonucleotide interference-PCR (ORNi-PCR) followed real-time PCR or droplet digital (ddPCR) single-nucleotide biopsy. A model cell-free DNA was used to demonstrate that ORNi-PCR-based methods more mutant than conventional ddPCR. useful early PDAC diagnosis.
Language: Английский
Citations
1
Abdominal Radiology, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 28, 2024
Language: Английский
Citations
1